European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 

Renal denervation in severe hypertension

ESC Congress 2012 Press Conference

Date & Time:  Monday 27 August, 12:40-13:20

Topic(s):  Hypertension

Chairs:Felix MAHFOUD (Germany)
 Adrian BRADY (United Kingdom)

Spokesperson

Prof Jose Ramon Gonzalez Juanatey (Spain)

 ‭(Hidden)‬ Content Editor Web Part

Spokespersons

name (country) Prof Jose Ramon Gonzalez Juanatey (Spain)  
declaration of interest declaration of interest
CV CV




ESC Congress 2012 in Munich

Renal denervation – a new possibility of non-pharmacological treatment of heart failure

 

press release
press release
 
Milos TABORSKY (Czech Republic)Refers to session: State of the Art - Novel concepts in heart failure treatments presentation slides presentation slides

Renal denervation does not involve any pharmacological treatment. It is a multiple application of radiofrequency energy using a thin catheter via the femoral artery and a long-term "denervation" of the sympathetic nerves around the renal arteries. The aim of this pilot study was to compare the outcomes of patients with advanced heart failure receiving standard pharmacological treatment or renal denervation.

conference webcastwebcast



ESC Congress 2012 in Munich
Renal denervation treats resistant hypertension in real world patient populationspress release
press release
 
Darren MYLOTTE (Ireland)Refers to session:  Poster session 5: Renal denervation therapy in hypertension presentation slides presentation slides

 

Transcatheter renal denervation represents a novel therapy for treating patients with treatment resistant hypertension, a condition which greatly increases the risk of myocardial infarction and stroke. The Symplicity Hypertension I and II studies have suggested that this procedure significantly lowers blood pressure in these patients with few remaining options in terms of treatment.

conference webcastwebcast



ESC Congress 2012 in Munich
Renal denervation improves blood pressure and arterial stiffness press release
press release
 
Klaas Frederik FRANZEN (Germany)Refers to session: Poster session 5: Renal denervation therapy in hypertension 
presentation slides presentation slides

Findings suggest that renal denervation regenerates blood vessels and could reduce cardiovascular events. Malignant arterial hypertension was historically treated with surgical thoracolumbar splanchnicectomy. In 2009 the concept of sympathectomy was reintroduced with intravasal catheter-based percutaneous renal sympathetic denervation (RDN) used in patients suffering from resistant arterial hypertension.

conference webcastwebcast




ESC Congress 2012 in Munich
Renal denervation achieves significant and sustained blood pressure reductionpress release
press release
 
Michael Bohm (Germany)Refers to session:  Renal denervation in hypertension presentation slides presentation slides
Treatment resistant hypertension is blood pressure that remains persistently high despite at least three prescription blood pressure medications, including a diuretic. This condition puts approximately 120 million people worldwide at risk of premature death from kidney disease and cardiovascular events such as stroke, heart attack and heart failure. It is one of the most challenging forms of hypertension to manage because it does not respond to blood pressure lowering drugs.conference webcastwebcast



ESC Congress 2012 in Munich
Renal sympathetic denervation improves physical and mental health in resistant hypertensionpress release
press release
 
Denise FISCHER (Germany)Refers to session:  Renal denervation in hypertension presentation slides presentation slides

Catheter-based renal sympathetic denervation (RDN)  improves anxiety, depression, quality of life and stress in patients with resistant hypertension.Arterial hypertension is often associated with several psychological comorbidities, such as anxiety and panic disorders, leading to impaired quality of life. RDN is a novel treatment option for patients with resistant hypertension and has been shown to reduce local and whole-body sympathetic activity and blood pressure.

conference webcastwebcast